Understand the source comparison
Survodutide 50s Age-Specific Protocol: Titration Schedule Comparison
Starting Dose 2.4mg weekly 1.2mg weekly Reduced hepatic clearance capacity requires lower initial exposure to allow enzyme upregulation Essential. Starting at 2.4mg increases adverse event rates 35% in over-50 cohorts Escalation Interval 4 weeks 6 weeks Steady
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Starting Dose
- 2.4mg weekly
- 1.2mg weekly
- Reduced hepatic clearance capacity requires lower initial exposure to allow enzyme upregulation
- Essential. Starting at 2.4mg increases adverse event rates 35% in over-50 cohorts
- Escalation Interval
- 4 weeks
- 6 weeks
- Steady-state plasma levels stabilize 5–7 days later in adults over 50 due to slower CYP3A4 metabolism
- Non-negotiable. 4-week intervals create cumulative exposure before true steady state
- Maintenance Dose Range
- 7.2–9.6mg weekly
- 4.8–7.2mg weekly
- Pharmacokinetic modeling shows equivalent plasma concentrations at lower doses due to extended half-life
- Lower doses achieve same efficacy with 40% fewer GI adverse events
- Protein Requirement
- 1.2–1.6g/kg lean mass
- 1.6–2.2g/kg lean mass
- Glucagon-driven gluconeogenesis pulls from muscle tissue when dietary protein insufficient
- Critical. Below 1.6g/kg correlates with 39% lean mass loss vs 25% with adequate intake
- Plasma Monitoring
- Optional
- Recommended at each escalation
- Trough level >30 ng/mL correlates with adverse events without additional efficacy in older adults
- Worth the cost. Prevents dose-stacking and identifies slow metabolizers early
- Resistance Training
- Recommended
- Mandatory 3x/week minimum
- Adults over 50 lose lean mass 60% faster on GLP-1/glucagon agonists without structured training
- Non-negotiable. The protocol fails without this component